Top stories in cardiology: No difference between dabigatran, aspirin for stroke prevention; pulsed field ablation safe

The top story in cardiology last week was research that found there was no significant difference between dabigatran and aspirin in preventing recurrent stroke in patients with an embolic stroke of undetermined source.

Other highlights were from the Heart Rhythm Society Annual Scientific Sessions and the National Lipid Association Scientific Sessions and included data that indicated pulsed field ablation safely isolated pulmonary veins with excellent durability in patients with paroxysmal atrial fibrillation, findings that suggested catheter ablation lowered recurrence of atrial fibrillation across a range of age groups compared with drug therapy while also reducing mortality rates in patients younger than 65 years, the National Lipid Association’s statement that price reductions of PCSK9 inhibitors contributed to greater cost-effectiveness and a presenter who said health care providers should focus on recommending exercise for patients with dyslipidemia to decrease their LDL.

Dabigatran not superior to aspirin for prevention of recurrent stroke

There was no significant difference between dabigatran and aspirin in preventing recurrent stroke in patients with an embolic stroke of undetermined source, according to findings published in The New England Journal of Medicine. Read more.

Pulsed field ablation safe for paroxysmal atrial fibrillation

SAN FRANCISCO — Pulsed field ablation was able to safely isolate pulmonary veins with excellent durability in patients with paroxysmal atrial fibrillation, according to data presented at the Heart Rhythm Society Annual Scientific Sessions. Read more.

CABANA analysis: Age a factor in mortality after atrial fibrillation ablation

SAN FRANCISCO — Catheter ablation lowered recurrence of atrial fibrillation across a range of age groups compared with drug therapy, and reduced mortality rates in patients younger than 65 years, a speaker said. Read more.

Price reductions of PCSK9 inhibitors contributed to greater cost-effectiveness

MIAMI — As a result of price reductions for PCSK9 inhibitors from late 2018 and early 2019, the treatment may be expected to be cost-effective in patients with extremely high, very high and high risk for atherosclerotic CVD, according to a National Lipid Association statement presented at the association’s Scientific Sessions. Read more.

Exercise should be emphasized in patients with dyslipidemia

MIAMI — Given all of the recent guidelines on physical activity and CVD prevention, health care providers should focus on recommending exercise for patients with dyslipidemia to decrease their LDL, a speaker said. Read more.

The top story in cardiology last week was research that found there was no significant difference between dabigatran and aspirin in preventing recurrent stroke in patients with an embolic stroke of undetermined source.

Other highlights were from the Heart Rhythm Society Annual Scientific Sessions and the National Lipid Association Scientific Sessions and included data that indicated pulsed field ablation safely isolated pulmonary veins with excellent durability in patients with paroxysmal atrial fibrillation, findings that suggested catheter ablation lowered recurrence of atrial fibrillation across a range of age groups compared with drug therapy while also reducing mortality rates in patients younger than 65 years, the National Lipid Association’s statement that price reductions of PCSK9 inhibitors contributed to greater cost-effectiveness and a presenter who said health care providers should focus on recommending exercise for patients with dyslipidemia to decrease their LDL.

Dabigatran not superior to aspirin for prevention of recurrent stroke

There was no significant difference between dabigatran and aspirin in preventing recurrent stroke in patients with an embolic stroke of undetermined source, according to findings published in The New England Journal of Medicine. Read more.

Pulsed field ablation safe for paroxysmal atrial fibrillation

SAN FRANCISCO — Pulsed field ablation was able to safely isolate pulmonary veins with excellent durability in patients with paroxysmal atrial fibrillation, according to data presented at the Heart Rhythm Society Annual Scientific Sessions. Read more.

CABANA analysis: Age a factor in mortality after atrial fibrillation ablation

SAN FRANCISCO — Catheter ablation lowered recurrence of atrial fibrillation across a range of age groups compared with drug therapy, and reduced mortality rates in patients younger than 65 years, a speaker said. Read more.

Price reductions of PCSK9 inhibitors contributed to greater cost-effectiveness

MIAMI — As a result of price reductions for PCSK9 inhibitors from late 2018 and early 2019, the treatment may be expected to be cost-effective in patients with extremely high, very high and high risk for atherosclerotic CVD, according to a National Lipid Association statement presented at the association’s Scientific Sessions. Read more.

Exercise should be emphasized in patients with dyslipidemia

MIAMI — Given all of the recent guidelines on physical activity and CVD prevention, health care providers should focus on recommending exercise for patients with dyslipidemia to decrease their LDL, a speaker said. Read more.